#China #Shanghai #financial results #Hengrui Pharma #Innovative Drugs

Hengrui Pharma Reports Strong First Half of 2026 Financial Results

Hengrui Pharma, a leading global biopharmaceutical company based in Shanghai, unveiled its financial performance for the first half of 2026, highlighting a strong growth trajectory fueled by a commitment to innovation and strategic globalization initiatives. The firm reported a revenue of RMB 15.46 billion, with drug sales reaching RMB 13.95 billion, marking a year-over-year growth of 1.87%. Particularly notable was the 16.38% increase in sales of innovative drugs, which accounted for 63.16% of total drug sales, demonstrating Hengrui's successful focus on higher-value therapeutics.

Financial Highlights

In terms of profitability, net profits attributable to shareholders stood at RMB 4.47 billion, a modest rise of 0.34% from the previous year. Investment in research and development (R&D) also remained robust at RMB 4.61 billion, representing 29.8% of total revenue. This significant investment underscores Hengrui's dedication towards enhancing its pipeline of innovative medicines and maintaining a competitive edge in the industry.

Pipeline and Regulatory Highlights

The company made substantial strides in advancing its product pipeline in China, having secured approval for seven innovative products during this reporting period. This included two Class 1 and one Class 2 medicines and additional indications for existing treatments. By the reporting period's conclusion, Hengrui had nine marketing applications under review with the National Medical Products Administration of China.

The clinical program remains promising, with 17 trials in Phase III, 22 in Phase II, and 10 in Phase I development stages. Noteworthy advancements include a dual receptor agonist for type 2 diabetes, ribupatide injection, which showed positive results in two Phase III studies, and progress with HRS-7535, an oral GLP-1 receptor agonist that has met key endpoints at Week 44 in a clinical trial for obesity.

Global Partnerships and Business Development

In line with its globalization strategy, Hengrui has actively sought diverse collaborative models. Since 2023, the company has finalized 13 international business development transactions, encompassing licensing agreements and strategic alliances with major pharmaceutical entities like BMS and GSK. Collectively, these potential transactions were valued at approximately USD 42 billion. Furthermore, Hengrui’s subsidiary Kailera Therapeutics successfully launched an IPO on Nasdaq, marking significant progress in its corporate development.

Scientific Recognition

Hengrui's commitment to scientific research has been acknowledged globally, with 204 research papers published in respected academic journals during this period. The company showcased its advancements at the American Society of Clinical Oncology Annual Meeting, receiving acceptance for 91 studies, including 11 oral presentations, marking a record for the firm. Additional findings in other fields were presented at esteemed conferences, including the American Diabetes Association and the International Stroke Conference.

Outlook

Looking ahead, Hengrui Pharma remains optimistic about its growth trajectory, emphasizing its dual-focus strategy targeting both oncology and chronic diseases. Plans include enhancing global R&D capabilities and diversifying international collaborations, aimed at delivering sustainable, long-term value while ensuring that innovative therapies reach patients around the globe. As the global pharmaceutical landscape evolves, Hengrui is poised to continue its mission of innovation, bringing high-quality therapies to the forefront of healthcare.

Through its ongoing commitment to innovation and global partnerships, Hengrui Pharma is reinforcing its position as a key player in the biopharmaceutical industry while striving to address unmet medical needs worldwide.